BMS Jumps Ahead With LAG-3 Melanoma Data

Bristol Myers Squibb Company reported the first successful Phase III data investigating a LAG-3 antibody in cancer on 25 March, and positive findings in combination with Opdivo (nivolumab) could set the stage for a new combination of checkpoint inhibitors. Though the data are early, the LAG-3 candidate used with the PD-1 inhibitor met the primary endpoint of progression-free survival in patients with previously untreated metastatic or unresectable melanoma.